KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Payables (2016 - 2025)

Eli Lilly (LLY) has disclosed Payables for 17 consecutive years, with $5.4 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Payables rose 17.57% year-over-year to $5.4 billion, compared with a TTM value of $5.4 billion through Dec 2025, up 17.57%, and an annual FY2025 reading of $5.4 billion, up 17.57% over the prior year.
  • Payables was $5.4 billion for Q4 2025 at Eli Lilly, up from $4.3 billion in the prior quarter.
  • Across five years, Payables topped out at $5.4 billion in Q2 2025 and bottomed at $1.4 billion in Q1 2022.
  • Average Payables over 5 years is $3.0 billion, with a median of $2.7 billion recorded in 2021.
  • The sharpest move saw Payables skyrocketed 89.91% in 2021, then dropped 12.58% in 2022.
  • Year by year, Payables stood at $2.6 billion in 2021, then increased by 15.32% to $2.9 billion in 2022, then grew by 27.82% to $3.8 billion in 2023, then rose by 21.43% to $4.6 billion in 2024, then rose by 17.57% to $5.4 billion in 2025.
  • Business Quant data shows Payables for LLY at $5.4 billion in Q4 2025, $4.3 billion in Q3 2025, and $5.4 billion in Q2 2025.